AstraZeneca puts down $185M upfront for PhI oral GLP-1 as it shoots for next-gen win
AstraZeneca has recruited a new star to its budding GLP-1 show, picking up an early-stage oral candidate from China’s Eccogene in a deal featuring $185 million upfront.
While it trails far behind GLP-1 leaders like Novo Nordisk and Eli Lilly — which just won an approval for tirzepatide (Zepbound) in weight loss — the company is betting that this oral alternative will become a “best in class” option, both as a monotherapy and in combinations. Like the established players, it will be eyeing type 2 diabetes, weight loss and more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.